MARKET

ASND

ASND

Ascendis Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

139.13
-1.34
-0.95%
After Hours: 139.13 0 0.00% 16:00 01/17 EST
OPEN
140.15
PREV CLOSE
140.47
HIGH
141.88
LOW
136.67
VOLUME
216.78K
TURNOVER
--
52 WEEK HIGH
142.94
52 WEEK LOW
66.12
MARKET CAP
6.64B
P/E (TTM)
-33.7399
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ASND and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ASND News

  • Morgan Stanley Maintains Overweight on Ascendis Pharma, Raises Price Target to $148
  • Benzinga.21h ago
  • The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics
  • Benzinga.1d ago
  • Ascendis Pharma A/S Provides Pipeline Update and Reviews Progress Towards Vision 3x3 at 38th Annual J.P. Morgan Healthcare Conference
  • Benzinga.4d ago
  • Ascendis Pharma A/S Provides Pipeline Update and Reviews Progress Towards Vision 3x3 at 38th Annual J.P. Morgan Healthcare Conference
  • Benzinga.5d ago

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About ASND

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop sustained release prodrug therapies with several product candidates in clinical and preclinical development. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications. In addition to TransCon hGH, the Company has developed a pipeline of long-acting prodrug product candidates, such as TransCon Treprostinil for the treatment of pulmonary arterial hypertension (PAH), TransCon Peptides for the treatment of diabetes and TransCon Ranibizumab for the treatment of ophthalmology. It is also using its TransCon technology platform to develop TransCon Parathyroid Hormone (TransCon PTH) for hypoparathyroidism, a rare endocrine disorder of calcium and phosphate metabolism.
More

Webull offers Ascendis Pharma A/S (ASND) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.